Business and Finance

CDMO’s financial commitment will feature construction of a new GMP clinical trial development facility

Financial commitment is predicted to more than double the biopharma site’s manufacturing capabilities

Transaction expands CDMO’s services, including more solutions surrounding commercial manufacturing

Five-year deal covers manufacturing of molecules, ranging from monoclonal antibodies to antibody-drug conjugates

Subject to regulatory approval, CDMO will produce mRNA vaccine on a commercial scale

The Discovery Centre will be powered by AI technology, robotics, among other features

Transaction is anticipated to further Novo’s research in the field of RNAi therapeutics

Acquisition of biopharma company features sotatercept, which is in Phase III trials for the treatment of pulmonary arterial hypertension

Financial commitment expected to increase plant's process development and manufacturing capacity

Industrialized collaboration is critical to taking next-generation cell and gene therapies to the next level—if companies can build on pandemic-partnering momentum

Separation process expected to be completed in 18-24 months

Expansion expected to more than double the plant’s footprint

CDMO’s expansion of Hopkinton, MA facility will include seven new ISO 7 cGMP suites

Deal expected to boost firm’s offerings via FDS's delivery system services

Partnership further increases investment firm’s repertoire in healthcare space

Boston area facility will focus heavily on cold chain services

Parties expect improved design and selection of eCOAs in decentralized clinical trials

ScriptDrop, Adheris Health collaborate to assist patients with their medication regimens

Award will support research based on use of real-world evidence in clinical oncology setting

Acquisition reportedly increases AI accessibility across life sciences organizations

Development project features additional manufacturing suites, expansion of storage capabilities

Facility features cell storage for CAR-T cell treatments

mRNA jab maker plans to initially produce 50 million Covid vaccine doses per year

Deal provides ten23 with drug product development, biologic manufacturing experience

Biologics manufacturer to construct new C&GT facility to support expansion